Familial hypercholesterolemia: Current limitations and future breakthroughs

Area of Science:

• Cardiovascular Genetics
• Metabolic Disorders
• Pharmacogenomics

Background:

• Familial hypercholesterolemia (FH) is an inherited condition leading to extremely high low-density lipoprotein cholesterol (LDL-C) levels.
• Genetic mutations, particularly in the LDLR gene, cause FH, resulting in early-onset cardiovascular disease, xanthomas, and corneal arcus.
• Despite available treatments, over 90% of FH cases are undiagnosed, highlighting a critical gap in public health.

Purpose of the Study:

• To review current diagnostic and management strategies for Familial hypercholesterolemia.
• To explore emerging therapeutic approaches, including novel drug classes and gene therapies.
• To emphasize the importance of early detection and comprehensive management for cardiovascular risk reduction.

Main Methods:

• Literature review of genetic mutations, clinical manifestations, and treatment outcomes in FH.
• Analysis of current therapeutic guidelines and emerging treatment modalities.
• Discussion of diagnostic challenges and future research directions in FH.

Main Results:

• Statins are the cornerstone of FH treatment, often requiring combination therapy with Ezetimibe or PCSK9 inhibitors.
• Severe FH cases may show limited response to conventional therapies, necessitating advanced interventions.
• Gene testing, precision medicine, and novel therapies like AAV-mediated gene therapy and CRISPR offer future treatment potential.

Conclusions:

• Improved diagnostic pathways and enhanced treatment strategies are crucial for managing FH effectively.
• Lifestyle modifications, including diet and exercise, are fundamental adjuncts to pharmacotherapy.
• Continued research into FH genetics and innovative therapies is essential to reduce the significant cardiovascular burden associated with this disorder.